よむ、つかう、まなぶ。
【参考資料３】【英版R4.1.17】Nippon AMR One Health Report (NAOR) 2020 (36 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_23261.html |
| 出典情報 | 国際的に脅威となる感染症対策関係閣僚会議 薬剤耐性ワンヘルス動向調査検討会（第9回 1／17）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
Table 41. Facility Types
Conventional
Unit-style
100 (73.0%)
Community-based
50 (36.5%)
Small transitional
14 (10.2%)
4 (2.9%)
Unit-style small
transitional
1 (0.7%)
Table 42. Medical devices used by patients using antimicrobials [Multiple answers] n=70 *Missing values: 10
Type of medical device
Number of people (%)
Peripheral route (inserted for the purpose of treating the infection)
Indwelling urethral catheter
Gastrostomy tube
Nasogastric tube
Nephrostomy/cystostomy tube
12 (17.1 %)
6 (8.6%)
4 (5.7%)
3 (4.3%)
1 (1.4%)
Other (pacemaker)
2 (2.9 %)
Peripheral route (inserted prior to the infection)
0
Self-inserted catheter
0
Colostomy equipment
0
Not using a medical device
49 (70.0%)
Total
70
Table 43. Focus of infection undergoing treatment [Multiple answers] n=74 *Missing values: 2
Focus of infection or diagnosis
Urinary tract infection
Number of people (%)
23 (31.1%)
Pneumonia
11 (14.9%)
Upper respiratory tract infection
9 (12.2%)
Bronchitis
7 (9.5%)
Cellulitis
4 (5.4%)
Gastroenteritis
0
Unknown
6 (8.1%)
Other
14 (18.9%)
Described above) The breakdown of the 14 classed as Other is as follows: bronchitis or pneumonia, 2; pressure ulcers, 2; ingrown nail
inflammation, 2; erythroderma, 1; systemic dermatitis, 1; cholecystitis, 1; gallstones, 1; digestive system, 1; upper or lower respiratory tract
infection, 1; upper respiratory tract infection or complicated cystitis, 1; pneumonia or urinary tract infection, 1.
Table 44. Main antimicrobials used to treat urinary tract infections and pneumonia [Multiple answers]
n
Urinary tract infection
23
Pneumonia
11
Main antimicrobials
・Fluoroquinolones
・3rd generation cephalosporins
・Penicillins
・2nd generation cephalosporins
・3rd generation cephalosporins
・Fluoroquinolones
・Carbapenems
・Macrolides
・3rd generation cephalosporins and fluoroquinolones
Number of people (%)
12 (52.2%)
7 (30.4%)
3 (13.0%)
1 ( 4.3%)
5 (45.5%)
3 (27.3%)
1 ( 9.1%)
1 ( 9.1%)
1 ( 9.1%)
(2) Animals
1) Bacteria derived from food-producing animals
Source: Japanese Veterinary Antimicrobial Resistance Monitoring System (JVARM)
Under the JVARM, antimicrobial susceptibility tests are performed using the broth microdilution method
according to the CLSI guidelines. For agents with a BP established by the CLSI, susceptibility was interpreted
using the CLSI Criteria. The BPs of the other antimicrobial agents used EUCAST values or were determined
microbiologically (midpoint of a bimodal MIC distribution).
35
Conventional
Unit-style
100 (73.0%)
Community-based
50 (36.5%)
Small transitional
14 (10.2%)
4 (2.9%)
Unit-style small
transitional
1 (0.7%)
Table 42. Medical devices used by patients using antimicrobials [Multiple answers] n=70 *Missing values: 10
Type of medical device
Number of people (%)
Peripheral route (inserted for the purpose of treating the infection)
Indwelling urethral catheter
Gastrostomy tube
Nasogastric tube
Nephrostomy/cystostomy tube
12 (17.1 %)
6 (8.6%)
4 (5.7%)
3 (4.3%)
1 (1.4%)
Other (pacemaker)
2 (2.9 %)
Peripheral route (inserted prior to the infection)
0
Self-inserted catheter
0
Colostomy equipment
0
Not using a medical device
49 (70.0%)
Total
70
Table 43. Focus of infection undergoing treatment [Multiple answers] n=74 *Missing values: 2
Focus of infection or diagnosis
Urinary tract infection
Number of people (%)
23 (31.1%)
Pneumonia
11 (14.9%)
Upper respiratory tract infection
9 (12.2%)
Bronchitis
7 (9.5%)
Cellulitis
4 (5.4%)
Gastroenteritis
0
Unknown
6 (8.1%)
Other
14 (18.9%)
Described above) The breakdown of the 14 classed as Other is as follows: bronchitis or pneumonia, 2; pressure ulcers, 2; ingrown nail
inflammation, 2; erythroderma, 1; systemic dermatitis, 1; cholecystitis, 1; gallstones, 1; digestive system, 1; upper or lower respiratory tract
infection, 1; upper respiratory tract infection or complicated cystitis, 1; pneumonia or urinary tract infection, 1.
Table 44. Main antimicrobials used to treat urinary tract infections and pneumonia [Multiple answers]
n
Urinary tract infection
23
Pneumonia
11
Main antimicrobials
・Fluoroquinolones
・3rd generation cephalosporins
・Penicillins
・2nd generation cephalosporins
・3rd generation cephalosporins
・Fluoroquinolones
・Carbapenems
・Macrolides
・3rd generation cephalosporins and fluoroquinolones
Number of people (%)
12 (52.2%)
7 (30.4%)
3 (13.0%)
1 ( 4.3%)
5 (45.5%)
3 (27.3%)
1 ( 9.1%)
1 ( 9.1%)
1 ( 9.1%)
(2) Animals
1) Bacteria derived from food-producing animals
Source: Japanese Veterinary Antimicrobial Resistance Monitoring System (JVARM)
Under the JVARM, antimicrobial susceptibility tests are performed using the broth microdilution method
according to the CLSI guidelines. For agents with a BP established by the CLSI, susceptibility was interpreted
using the CLSI Criteria. The BPs of the other antimicrobial agents used EUCAST values or were determined
microbiologically (midpoint of a bimodal MIC distribution).
35